| Literature DB >> 31275930 |
Chen Xu1,2,3, Ozioma Udochukwu Akakuru1, Jianjun Zheng4, Aiguo Wu1.
Abstract
Diseases caused by bacterial infections, especially drug-resistant bacteria have seriously threatened human health throughout the world. It has been predicted that antimicrobial resistance alone will cause 10 million deaths per year and that early diagnosis and therapy will efficiently decrease the mortality rate caused by bacterial infections. Considering this severity, it is urgent to develop effective methods for the early detection, prevention and treatment of these infections. Until now, numerous efforts based on nanoparticles have been made to detect and kill pathogenic bacteria. Iron oxide-based magnetic nanoparticles (MNPs), as potential platforms for bacteria detection and therapy, have drawn great attention owing to their magnetic property. These MNPs have also been broadly used as bioimaging contrast agents and drug delivery and magnetic hyperthermia agents to diagnose and treat bacterial infections. This review therefore overviews the recent progress on MNPs for bacterial detection and therapy, including bacterial separation and enrichment in vitro, bacterial infection imaging in vivo, and their therapeutic activities on pathogenic bacteria. Furthermore, some bacterial-specific targeting agents, used to selectively target the pathogenic bacteria, are also introduced. In addition, the challenges and future perspective of MNPs for bacterial diagnosis and therapy are given at the end of this review. It is expected that this review will provide a better understanding toward the applications of MNPs in the detection and therapy of bacterial infections.Entities:
Keywords: bacterial infection; bacterial target molecules; detection; magnetic nanoparticles; therapy
Year: 2019 PMID: 31275930 PMCID: PMC6591363 DOI: 10.3389/fbioe.2019.00141
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Scheme 1MNPs based nanoparticles for bacterial detection and therapy.
Examples of bacterial target molecules conjugated MNPs for bacterial detection.
| Antibodies | Anti- | Bacterial suspension | Fluorescence | 10 CFU/mL | Park et al., | |
| monoclonal antibody (MAb)-conjugated MNPs | Bacterial suspension | Colorimetric detection | 2 × 10 cells | Shim et al., | ||
| monoclonal antibodies (mAbs)-conjugated magnetic beads | Bacterial suspension | SERS and fluorescence | 102 cells/mL | Jang et al., | ||
| Vancomycin | Fe3O4/Van/PEG magnetic nanocarrier; Van-PEG-PLL-MNPs | Mixed solutions | PCR | 10 CFU/mL | Zhu et al., | |
| Van-PEGylated-MNPs | Bacterial suspension | PCR | 30 CFU/mL | Meng et al., | ||
| Fe3O4@Ag-Van MNPs and Au@Ag NPs | Broad range of Gram-positive and Gram-negative bacteria | Bacterial suspension | SERS | 5 × 102 cells/mL | Wang et al., | |
| Vancomycin and ALP-IgG | ALP-IgG-Van- magnetic beads | Water/milk/urine and saliva | Fluorescence | 3.3 CFU/mL | Yang et al., | |
| Streptavidin | MNP@Strep/Ag | knee joint fluid | SERS | – | Fargašová et al., | |
| Amoxicillin | Amoxicillin-conjugated Fe3O4 | Mixed solutions | MALDI MS | 103 CFU/mL | Hasan et al., | |
| Antimicrobial peptide | AMP modified Fe3O4 NPs and 4-MPBA modified Au@Ag-GO nanocomposites | Whole blood | SERS | 10 CFU/mL | Yuan et al., | |
| T4 bacteriophage | T4 bacteriophage modified Fe3O4 | Bacterial suspension | – | – | Liana et al., | |
| T7 bacteriophage | T7 bacteriophage-conjugated magnetic beads | Drinking water | Colorimetric detection | 10 CFU/mL | Chen et al., | |
| PAP1 bacteriophage | PAP1-functionalized magnetic beads | Bacterial suspension | Colorimetric detection | 2 × 102 CFU/mL | He et al., | |
| E. coli specific DNAzyme | MNP-DNAzyme-AChE (MDA) complex and DNA-templated fluorescent silver nanoclusters | Bacterial suspension | Fluorescence | 60 CFU/mL | Zheng et al., | |
| Aptamers | Fe3O4-Ce6-Aptamer | Blood samples from mice | Fluorescence | 10 CFU/mL | Wang et al., | |
| Aptamer modified Fe3O4 NPs and Co2+ enhanced N-(aminobutyl)-N-(ethylisoluminol) (ABEI) functional flowerlike gold nanoparticles | Fluorescence | 32 CFU/mL | Hao et al., | |||
| Aptamer-functionalized Fe3O4@silica | Whole blood | Fluorescence | 682 CFU | Borsa et al., |
Figure 1(A) Illustration of the preparation of the bioconjugated magnetic clusters with antibodies and (B) the different selective targets of Salmonella typhimurium for different antigens. Reprinted with permission from Kim et al. (2016). Copyright (2016) American Chemical Society.
Figure 2Schematic diagram of a selective filtration method for the colorimetric detection of Escherichia coli. Reprinted with permission from Kim et al. (2018). Copyright (2018) American Chemical Society. (A) Immunomagnetic separation for target bacteria using MNP conjugates; (B) selective filtration of target bacteria-conjugates complexes, and (C) colored spots on the filter membrane by target bacteria-conjugates (upper) and enhanced colorimetric spots by enzymatic amplification with precipitation on the bacteria-conjugate surfaces (lower).
Figure 3(A) Characterization of the Au-coated MNPs: (a) absorption spectra of MNPs (red line) and Au-coated MNPs (blue line), (b) TEM image of Au-coated MNPs bound with Salmonella typhimurium; (B) schematic illustration and the corresponding optical images before (a) and after (b) magnetophoretic chromatography. Reprinted with permission from Kwon et al. (2013). Copyright (2013) American Chemical Society.
Figure 4Au-coated magnetic NPs (AuMNPs) for Staphylococcus aureus capture, separation and detection. (A) Illustration of synthetic route of AuMNPs, (B) illustration of the detection procedures for S. aureus via a SERS method, (C) SERS spectra with various concentrations of S. aureus (from 101 to105 cells/mL), and (D) calibration curve for S. aureus at a concentration ranging from 101 to 105 cells/mL obtained by using SERS intensity at 1,077 cm−1. Reprinted with permission from Wang et al. (2016). Copyright (2016) American Chemical Society.
The minimum inhibitory concentrations (MIC) of various MNPs toward different bacteria of biofilms.
| Fe3O4 | 4–10 | 10 | – | – | Thukkaram et al., | |
| Fe3O4 | ≤ 18 | 100 | – | – | Taylor and Webster, | |
| Ag/Fe3O4 | 20 | 3 | – | – | Ghaseminezhad and Shojaosadati, | |
| Fe3O4 | 10 | 9.2 | ||||
| Fe3O4@PEG-Ag | 20–25 | 16 | – | – | Zomorodian et al., | |
| Fe3O4@PAA | 10 ± 2 | 8000 | Magnetic hyperthermia | – | Rodrigues et al., | |
| Fe3O4@APTES | 17 | 100 | – | – | Ranmadugala et al., | |
| CoFe2O4 | 16 ± 5 | 50 | – | – | Venkatesan et al., | |
| Fe3O4-TiO2 | – | 12.5 | Simulated solar irradiation | – | Ma et al., | |
| MNP-CSA-13 | 14 ± 2 | 1 | – | – | Niemirowicz et al., | |
| VancomycinPEG-chitosan-MnFe2O4 | 25 | 0.61 | – | Vancomycin | Esmaeili and Ghobadianpour, | |
| 0.78 | ||||||
| 0.78 | ||||||
| 0.98 | ||||||
| 39.06 | ||||||
| 78.12 | ||||||
| MNPs@Ag@HA | ~40 | 200 | Magnetic field | Gentamicin | Wang et al., | |
| MnFe2O4@PrBrT | 10 | 8 | Magnetic hyperthermia | – | Pu et al., | |
| 8 |
Figure 5MNPs for enhanced biofilm distribution under magnetic field. (A) Illustration of MNPs based antibiotic and Ag delivery for inactivating the embedded bacteria with or without an external magnetic field, and (B) Live/dead staining of 3D reconstructions of S. aureus biofilm and bacterial colonies of surviving S. aureus in biofilms after treatment without and with an applied magnetic field, respectively. Reprinted with permission from Wang et al. (2018d). Copyright (2018) American Chemical Society.